Connect with others who understand.

Sign up Log in
Resources
About myPHteam
Powered By
See answer

FDA Approves Ketamine-Like Drug for Severe Depression

Posted on March 18, 2019

By Carole Tanzer Miller and E.J. Mundell, HealthDay Reporters

WEDNESDAY, March 6, 2019 (HealthDay News) -- The U.S. Food and Drug Administration approved the nasal spray medication esketamine -- a relative of the club drug and anesthetic ketamine -- for use against severe depression.

Sold as Spravato, the fast-acting drug becomes the first new type of medicine approved in years against an illness that plagues millions of Americans.

In a statement, the FDA said Spravato should be used in conjunction with an antidepressant pill and is meant only for people whose depression has not responded to at least two other antidepressants.

Spravato -- a much less potent relative of the illicit club drug "Special K" -- comes with other restrictions, the FDA said. Ketamine can induce dissociation (feeling disconnected from one's surroundings) and sedation.

Because Spravato might act similarly for a minority of patients, the FDA said safeguards are warranted.

"Because of safety concerns, the drug will only be available through a restricted distribution system and it must be administered in a certified medical office where the health care provider can monitor the patient," said Dr. Tiffany Farchione. She's acting director of the Division of Psychiatry Products in the FDA's Center for Drug Evaluation and Research.

Patients will self-administer the nasal spray during visits to a medical clinic, and the spray cannot be taken home. A health care provider will monitor the patient until it is clear that he or she is ready to leave.

Ketamine came first

Approval of a medicine like Spravato is welcome news for patients like Jen Godfrey, who said she couldn't shake the "deep cloud" of depression that lingered even after she found an antidepressant she could tolerate. She turned to clinics that were dispensing the anesthetic ketamine "off-label" for help against depression.

A number of stressors had hit Godfrey hard -- five years of fertility treatment and an 80-pound weight gain during pregnancy that left her with persistent pain; a close relative's suicide; another who went missing; and her own divorce. It was all too much.

"The life stuff just had a gravitational pull," said the stay-at-home mom from Reno, Nev., who's in her mid-40s. "I just thought: I don't drink, I'm a good friend, a good mother, a good spouse -- I should be a lot happier."

Godfrey's search for relief pointed her towards ketamine. Low, intravenous doses have been found to boost mood and curb suicidal thoughts, but the FDA has never approved ketamine as a treatment for depression. And the American Psychiatric Association (APA) warns patients about the potential for abuse and the lack of large, long-term studies of its effectiveness.

Even so, ketamine clinics like the one treating Godfrey have sprung up across the United States.

"The lack of information [on ketamine] is really quite dramatic when you look at the proliferation of use in certain communities," said former APA President Dr. Alan Schatzberg. He helped write an APA statement about ketamine urging caution.

A new, safer alternative?

Spravato, the drug approved Tuesday, is touted as a much safer cousin of ketamine.

Speaking this week with National Public Radio, Courtney Billington, president of Janssen Neuroscience, said that, unlike ketamine, "the amount of active ingredient that's in this product is at a very, very low dose."

In four studies that led to its approval, Spravato performed well against placebo, the FDA said, showing a "statistically significant effect compared to placebo on the severity of depression, and some effect was seen within two days." That's a much faster time to symptom relief than many antidepressants.

One longer-term trial suggests that Spravato's benefit lasts, the FDA said.

Side effects can occur, however.

"The most common side effects experienced by patients treated with Spravato in the clinical trials were dissociation, dizziness, nausea, sedation, vertigo, decreased feeling or sensitivity (hypoesthesia), anxiety, lethargy, increased blood pressure, vomiting and feeling drunk," the agency said.

Because of these potential effects, people with high blood pressure or certain vascular disorders should not take Spravato, and people should get a night of "restful sleep" before attempting to drive after taking the drug.

Also, "Spravato may cause fetal harm and women of reproductive potential should consider pregnancy planning and prevention; women should not breastfeed while being treated," the FDA said.

A 'game-changer'

How do medicines like Spravato and ketamine help ease depression?

It's not clear, Schatzberg said. One common theory is that they affec the brain's response to the neurotransmitter glutamate. Neurotransmitters are chemicals that send signals from one part of the brain to another and from the brain to the body. Essentially, the thinking goes, these meds rewire the brain.

But Schatzberg, a professor of psychiatry and behavioral sciences at Stanford University, was part of a small study published online recently in The American Journal of Psychiatry. It suggested another explanation -- that ketamine somehow activates opioid receptors in the brain.

That's potentially troubling, he said.

"We could be exposing people to untoward consequences from a drug that works through an opioid mechanism," he said. With an opioid addiction crisis in full swing across the United States, "we need to study [ketamine] more," he added.

For her part, Godfrey said ketamine has been nothing short of a miracle for her. Before that, she had tried a series of antidepressants before finding one that helped a bit, and everything from acupuncture to yoga and meditation. But her gloom and pain never seemed to go away.

"I did not think that anything with this much relief and promise would come along in my lifetime, let alone now," Godfrey said. "It's a game-changer."

SOURCES: Jen Godfrey, Reno, Nev.; Alan Schatzberg, M.D., professor, psychiatry and behavioral sciences, Stanford University, Stanford, Calif., and former president, American Psychiatric Association; Robert Watson, M.D., owner, Sierra Ketamine Clinics, Reno, Nev.; U.S. Food and Drug Administration, news release, March 5, 2019; National Public Radio

Copyright © 2019 All rights reserved.

What do you think about this new treatment for depression? Share in the comments below!

 
Posted on March 18, 2019

A myPHteam Member

me too from grandchildren and great grand children

October 6, 2021
All updates must be accompanied by text or a picture.

We'd love to hear from you! Please share your name and email to post and read comments.

You'll also get the latest articles directly to your inbox.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service.
All updates must be accompanied by text or a picture.

Subscribe now to ask your question, get answers, and stay up to date on the latest articles.

Get updates directly to your inbox.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service.

Related Articles

Pulmonary arterial hypertension (PAH) is a serious condition that causes high blood pressure in t...

Targeting the Molecular Pathways That Cause PAH: What We Know

Pulmonary arterial hypertension (PAH) is a serious condition that causes high blood pressure in t...
If you’re living with pulmonary arterial hypertension (PAH), a type of pulmonary hypertension (PH...

New Pulmonary Arterial Hypertension Medications: 4 Advances in Treatment

If you’re living with pulmonary arterial hypertension (PAH), a type of pulmonary hypertension (PH...
Whether you have just been diagnosed or are several years into life with pulmonary arterial hyper...

8 Questions To Ask Your Pulmonologist About PAH Treatment

Whether you have just been diagnosed or are several years into life with pulmonary arterial hyper...
Shortness of breath is one of the most common symptoms of pulmonary arterial hypertension (PAH). ...

PAH and Shortness of Breath: How Does Treatment Help?

Shortness of breath is one of the most common symptoms of pulmonary arterial hypertension (PAH). ...
Dizziness and fainting are common symptoms of pulmonary arterial hypertension (PAH). Dizziness ma...

PAH Dizziness and Fainting: How Does Treatment Help?

Dizziness and fainting are common symptoms of pulmonary arterial hypertension (PAH). Dizziness ma...
Doctors recommend pulmonary hypertension (PH) treatments based on several different factors, incl...

5 Pulmonary Hypertension Medications and Treatment Options

Doctors recommend pulmonary hypertension (PH) treatments based on several different factors, incl...

Recent Articles

Members of myPHteam have asked others how their pulmonary arterial hypertension (PAH) relates to ...

Pulmonary Arterial Hypertension: How Are the Lungs and Heart Connected?

Members of myPHteam have asked others how their pulmonary arterial hypertension (PAH) relates to ...
Pulmonary hypertension (PH) can arise from many underlying causes and conditions.

End-Stage Pulmonary Hypertension: Symptoms and What To Expect

Pulmonary hypertension (PH) can arise from many underlying causes and conditions.
MyHealthTeam does not provide health services, and if you need help, we’d strongly encourage you ...

Crisis Resources

MyHealthTeam does not provide health services, and if you need help, we’d strongly encourage you ...
If you have a connective tissue disease like scleroderma, you may be wondering how else it affect...

Scleroderma in PAH: 4 Facts To Know

If you have a connective tissue disease like scleroderma, you may be wondering how else it affect...
Your body craves oxygen. In fact, each organ in your body, from your toe muscles to your brain, n...

How the Pulmonary Artery Functions: 5 Things To Know

Your body craves oxygen. In fact, each organ in your body, from your toe muscles to your brain, n...
Coughing is a rare but bothersome symptom of pulmonary arterial hypertension (PAH). This long-ter...

8 Tips To Manage Coughing From PAH

Coughing is a rare but bothersome symptom of pulmonary arterial hypertension (PAH). This long-ter...

Thank you for subscribing!

Become a member to get even more: